肾内科指南

订阅

MedSci主页 / 所有栏目 / 肾内科指南

上尿路疾病经皮穿刺途径诊疗安全共识

2021-02-25 中国医促会泌尿健康促进分会 现代泌尿外科杂志.2021.26(2):107-111.

上尿路

在微创外科时代，泌尿外科医生需要掌握经皮穿刺技术以适应微创技术快速法阵的需要，但是由于缺乏规范化培训及临床经验差别，上尿路经皮穿刺途径的诊疗措施开展并不广泛，且相关并发症时有发生。因此提高对该技术安全

中文标题：

上尿路疾病经皮穿刺途径诊疗安全共识

发布机构：

中国医促会泌尿健康促进分会

发布日期：

2021-02-25

简要介绍：

在微创外科时代，泌尿外科医生需要掌握经皮穿刺技术以适应微创技术快速法阵的需要，但是由于缺乏规范化培训及临床经验差别，上尿路经皮穿刺途径的诊疗措施开展并不广泛，且相关并发症时有发生。因此提高对该技术安全性的认识，对顺利开展上尿路疾病经皮穿刺途径诊疗有重要的指导意义。

相关资料下载：
[AttachmentFileName(sort=1, fileName=上尿路疾病经皮穿刺途径诊疗安全共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=464eb1c0020e079e, title=上尿路疾病经皮穿刺途径诊疗安全共识, enTitle=, guiderFrom=现代泌尿外科杂志.2021.26(2):107-111., authorId=0, author=, summary=在微创外科时代，泌尿外科医生需要掌握经皮穿刺技术以适应微创技术快速法阵的需要，但是由于缺乏规范化培训及临床经验差别，上尿路经皮穿刺途径的诊疗措施开展并不广泛，且相关并发症时有发生。因此提高对该技术安全, cover=https://img.medsci.cn/2021313/1615650521017_2020535.jpg, journalId=0, articlesId=null, associationId=1623, associationName=中国医促会泌尿健康促进分会, associationIntro=, copyright=0, guiderPublishedTime=Thu Feb 25 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>在微创外科时代，泌尿外科医生需要掌握经皮穿刺技术以适应微创技术快速法阵的需要，但是由于缺乏规范化培训及临床经验差别，上尿路经皮穿刺途径的诊疗措施开展并不广泛，且相关并发症时有发生。因此提高对该技术安全性的认识，对顺利开展上尿路疾病经皮穿刺途径诊疗有重要的指导意义。</p> </div> </div> </div>, tagList=[TagDto(tagId=56480, tagName=上尿路)], categoryList=[CategoryDto(categoryId=14, categoryName=肾内科, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=56480, guiderKeyword=上尿路, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11239, appHits=78, showAppHits=0, pcHits=417, showPcHits=11161, likes=2, shares=10, comments=10, approvalStatus=1, publishedTime=Sat Mar 13 23:54:01 CST 2021, publishedTimeString=2021-02-25, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sat Mar 13 23:48:51 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Thu Jan 04 14:20:59 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=上尿路疾病经皮穿刺途径诊疗安全共识.pdf)])
上尿路疾病经皮穿刺途径诊疗安全共识.pdf
下载请点击：
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1004768, encodeId=2ff21004e68ed, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499f5562353, createdName=ms8000001908550582, createdTime=Mon Aug 02 22:56:23 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964359, encodeId=22b69643597c, content=非常好！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4212365816, createdName=122e140em61(暂无昵称), createdTime=Mon May 10 20:02:40 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957993, encodeId=835195e993f2, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0415481656, createdName=ms3000001296912478, createdTime=Sun Apr 18 11:27:15 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956987, encodeId=36f995698e24, content=好共识！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Apr 14 18:11:19 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956237, encodeId=be4195623ecc, content=好文章！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Apr 12 18:07:20 CST 2021, time=2021-04-12, status=1, ipAttribution=)]
    2021-08-02 ms8000001908550582

    好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1004768, encodeId=2ff21004e68ed, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499f5562353, createdName=ms8000001908550582, createdTime=Mon Aug 02 22:56:23 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964359, encodeId=22b69643597c, content=非常好！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4212365816, createdName=122e140em61(暂无昵称), createdTime=Mon May 10 20:02:40 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957993, encodeId=835195e993f2, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0415481656, createdName=ms3000001296912478, createdTime=Sun Apr 18 11:27:15 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956987, encodeId=36f995698e24, content=好共识！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Apr 14 18:11:19 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956237, encodeId=be4195623ecc, content=好文章！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Apr 12 18:07:20 CST 2021, time=2021-04-12, status=1, ipAttribution=)]
    2021-05-10 122e140em61(暂无昵称)

    非常好！

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1004768, encodeId=2ff21004e68ed, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499f5562353, createdName=ms8000001908550582, createdTime=Mon Aug 02 22:56:23 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964359, encodeId=22b69643597c, content=非常好！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4212365816, createdName=122e140em61(暂无昵称), createdTime=Mon May 10 20:02:40 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957993, encodeId=835195e993f2, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0415481656, createdName=ms3000001296912478, createdTime=Sun Apr 18 11:27:15 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956987, encodeId=36f995698e24, content=好共识！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Apr 14 18:11:19 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956237, encodeId=be4195623ecc, content=好文章！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Apr 12 18:07:20 CST 2021, time=2021-04-12, status=1, ipAttribution=)]
    2021-04-18 ms3000001296912478

    好文章

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1004768, encodeId=2ff21004e68ed, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499f5562353, createdName=ms8000001908550582, createdTime=Mon Aug 02 22:56:23 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964359, encodeId=22b69643597c, content=非常好！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4212365816, createdName=122e140em61(暂无昵称), createdTime=Mon May 10 20:02:40 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957993, encodeId=835195e993f2, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0415481656, createdName=ms3000001296912478, createdTime=Sun Apr 18 11:27:15 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956987, encodeId=36f995698e24, content=好共识！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Apr 14 18:11:19 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956237, encodeId=be4195623ecc, content=好文章！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Apr 12 18:07:20 CST 2021, time=2021-04-12, status=1, ipAttribution=)]
    2021-04-14 jyzxjiangqin

    好共识！

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1004768, encodeId=2ff21004e68ed, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499f5562353, createdName=ms8000001908550582, createdTime=Mon Aug 02 22:56:23 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964359, encodeId=22b69643597c, content=非常好！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4212365816, createdName=122e140em61(暂无昵称), createdTime=Mon May 10 20:02:40 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957993, encodeId=835195e993f2, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0415481656, createdName=ms3000001296912478, createdTime=Sun Apr 18 11:27:15 CST 2021, time=2021-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956987, encodeId=36f995698e24, content=好共识！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Apr 14 18:11:19 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956237, encodeId=be4195623ecc, content=好文章！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon Apr 12 18:07:20 CST 2021, time=2021-04-12, status=1, ipAttribution=)]
    2021-04-12 jyzxjiangqin

    好文章！

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2017 EAU指南：上尿路尿路上皮癌

欧洲泌尿外科学会(EAU,European Association of Urology) · 2017-03-01

拓展阅读

2017 EAU指南：上尿路尿路上皮癌

欧洲泌尿外科学会(EAU,European Association of Urology) · 2017-03-01